Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-121 in moderate to severe acne vulgaris
NCT02932306Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing IDP-121 Lotion with IDP-121 Vehicle Lotion (2 arms). Primary endpoints: Absolute Change From Baseline in Mean Noninflammatory Lesion Count at 12 weeks, Absolute Change From Baseline in Mean Inflammatory Lesion Count at 12 weeks and 1 more. Started Nov 2015; status: completed.
02
Drugs
IDP-121
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02932306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932306.